A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers with a very low survival rate at 5 years. The use of chemotherapeutic agents results in only modest prolongation of survival and is generally associated with the occurrence of toxicity effects. Antibody-based i...

Descripción completa

Detalles Bibliográficos
Autores principales: Busato, Davide, Capolla, Sara, Durigutto, Paolo, Mossenta, Monica, Bozzer, Sara, Sblattero, Daniele, Macor, Paolo, Dal Bo, Michele, Toffoli, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685509/
https://www.ncbi.nlm.nih.gov/pubmed/38017492
http://dx.doi.org/10.1186/s12967-023-04745-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685509/
https://www.ncbi.nlm.nih.gov/pubmed/38017492
http://dx.doi.org/10.1186/s12967-023-04745-9

Ejemplares similares